optikira.com
Overview — OptiKira
http://www.optikira.com/overview
Α is the master regulator of the UPR, directing the cellular response towards the adaptive or terminal pathways. Our academic Founders made the seminal discovery that certain small molecule kinase inhibitors can effectively block the terminal pathway. They have demonstrated that these compounds, which they have named kinase-inhibiting RNase attenuators (KIRAs), can protect cells from degeneration in preclinical models of retinitis pigmentosa (RP) and diabetes. Subscribe to OptiKira Updates.
dualtherapeutics.com
Company
http://www.dualtherapeutics.com/About_Us/Company
Dual Therapeutics is an oncology start-up company developing novel therapeutics for prostate cancer, lung cancer, and acute lymphoblastic leukemia. Founded in 2013, the company’s technology is based on research developed and exclusively licensed from the Mount Sinai School of Medicine and Case Western Reserve University. Currently, Dual Therapeutics is at the development compound nomination milestone and expects to file its IND application and begin clinical studies in 2015. Sign Up for News Alerts.
optikira.com
News — OptiKira
http://www.optikira.com/news-1
Subscribe to OptiKira Updates.
dualtherapeutics.com
Technology | Dual Therapeutics
http://www.dualtherapeutics.com/info
Models, suggesting that it may meaningfully advance the standard of care for these diseases. Content Management Solutions by INSYTE Consulting Group, LLC. Sign Up for News Alerts.
dualtherapeutics.com
Scientific Advisory Board | Dual Therapeutics
http://www.dualtherapeutics.com/Article/Scientific-Advisory-Board
Chair: Goutham Narla, MD, PhD. Assistant Professor of Medicine. Case Western Reserve University. 2012 Harrington Distinguished Scholar. Donald McDonnell, PhD. Professor of Medicine,. William Hahn, PhD. Associate Professor of Medicine. Harvard Medical School,. Mohandas Narla, DSc. Vice President of Research,. New York Blood Center. Arnold Levine, PhD. Systems Biology Professor Emeritus,. Institute for Advanced Study. Kevin Shannon, MD. Professor of Pediatrics,. University of California, San Francisco.
dualtherapeutics.com
Leadership | Dual Therapeutics
http://www.dualtherapeutics.com/article
Amy Trainor, PhD. Amy Trainor, PhD, is a Venture Partner at BioMotiv. Previously, she spent over 30 years at AstraZeneca Pharmaceuticals where she led the neuroscience external partnership activities and directed global product teams in oncology and neuroscience. Dr. Trainor is an inventor on 20 issued US patents and is an author on multiple peer-reviewed publications. Theodore Torphy, PhD. Content Management Solutions by INSYTE Consulting Group, LLC. Sign Up for News Alerts.
dualtherapeutics.com
News | Dual Therapeutics
http://www.dualtherapeutics.com/pressroom
Dual Therapeutics Announces Strategic Collaboration with Bristol-Myers Squibb. January 8, 2016. Dual Therapeutics, a BioMotiv portfolio company, has partnered with BMS in a strategic collaboration to advance small molecule compounds for the treatment of cancer and other diseases. Dual will receive upfront and milestone payments that could total more than $255 million in addition to royalties on future sales of products from the collaboration. Click here to read more. June 23, 2014. Click here to read more.
dualtherapeutics.com
Scientific Founders | Dual Therapeutics
http://www.dualtherapeutics.com/Article/Scientific-Founders
Goutham Narla, MD, PhD. Goutham Narla, MD, PhD, is a medical geneticist and a physician scientist at University Hospitals / Case Western Reserve University and a Harrington Discovery Institute Distinguished Scholar. He has expertise in cancer genetics and mouse xenograft and transgenic models of prostate, lung, and other cancers with over 47 publications in the field. He is also the recipient of the early career award from the Howard Hughes Medical Institute. Matthew Galsky, MD. Michael Ohlmeyer, PhD.
dualtherapeutics.com
Management | Dual Therapeutics
http://www.dualtherapeutics.com/Article/Management
Amy Trainor, PhD. Amy Trainor, PhD, is a Venture Partner at BioMotiv. Previously, she spent over 30 years at AstraZeneca Pharmaceuticals where she led the neuroscience external partnership activities and directed global product teams in oncology and neuroscience. Dr. Trainor is an inventor on 20 issued US patents and is an author on multiple peer-reviewed publications. Content Management Solutions by INSYTE Consulting Group, LLC. Sign Up for News Alerts.
